Massachusetts General Hospital , Harvard Medical School
Concord, MA, United States
Dr. Stone is a Professor of Medicine at Harvard Medical School and the Edward A. Fox Chair of Medicine at the Massachusetts General Hospital.
Tuesday, November 14, 2023
2:00 PM – 2:15 PM PT
Disclosure(s): Abvie: Consultant (Ongoing); Amgen: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Argenx: Consultant (Ongoing); Aztrazeneca: Consultant (Terminated, December 31, 2022); Bristol Myers Squibb: Consultant (Ongoing), Grant/Research Support (Ongoing); Celgene: Consultant (Terminated, December 31, 2022); Chemocentryx: Consultant (Terminated, December 31, 2022); Chugai: Consultant (Terminated, December 31, 2022); GSK: Consultant (Terminated, December 31, 2022); Horizon Therapeutics: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); InflaRx: Consultant (Terminated, December 31, 2022); IQVIA: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Kyverna: Consultant (Terminated, December 31, 2022); Mirabio: Consultant (Terminated, December 31, 2022); NIH: Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing); PPD: Consultant (Ongoing); Prometheus: Consultant (Ongoing); Q32: Consultant (Ongoing); Regeneron: Consultant (Terminated, December 31, 2022); Roche-Genentech: Consultant (Ongoing); Roivant: Consultant (Terminated, December 31, 2022); Sanofi: Consultant (Ongoing), Grant/Research Support (Ongoing); Spruce Biosciences: Consultant (Terminated, December 31, 2022); Star Therapeutics: Consultant (Ongoing); Steritas: Chair, Scientific Advisory Board (no fiduciary responsibilities) (Ongoing); ZenasBio: Consultant (Ongoing)
236: IgG4-related disease: How to identify, diagnose and treat
Tuesday, November 14, 2023
6:00 PM – 8:00 PM PT
Disclosure(s): Abvie: Consultant (Ongoing); Amgen: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Argenx: Consultant (Ongoing); Aztrazeneca: Consultant (Terminated, December 31, 2022); Bristol Myers Squibb: Consultant (Ongoing), Grant/Research Support (Ongoing); Celgene: Consultant (Terminated, December 31, 2022); Chemocentryx: Consultant (Terminated, December 31, 2022); Chugai: Consultant (Terminated, December 31, 2022); GSK: Consultant (Terminated, December 31, 2022); Horizon Therapeutics: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); InflaRx: Consultant (Terminated, December 31, 2022); IQVIA: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Kyverna: Consultant (Terminated, December 31, 2022); Mirabio: Consultant (Terminated, December 31, 2022); NIH: Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing); PPD: Consultant (Ongoing); Prometheus: Consultant (Ongoing); Q32: Consultant (Ongoing); Regeneron: Consultant (Terminated, December 31, 2022); Roche-Genentech: Consultant (Ongoing); Roivant: Consultant (Terminated, December 31, 2022); Sanofi: Consultant (Ongoing), Grant/Research Support (Ongoing); Spruce Biosciences: Consultant (Terminated, December 31, 2022); Star Therapeutics: Consultant (Ongoing); Steritas: Chair, Scientific Advisory Board (no fiduciary responsibilities) (Ongoing); ZenasBio: Consultant (Ongoing)